Abstract

Steviol glycosides are the intensely sweet components of extracts from Stevia rebaudiana. These molecules comprise an invariant steviol aglycone decorated with variable glycans and could widely serve as a low-calorie sweetener. However, the most desirable steviol glycosides Reb D and Reb M, devoid of unpleasant aftertaste, are naturally produced only in trace amounts due to low levels of specific β (1–2) glucosylation in Stevia. Here, we report the biochemical and structural characterization of OsUGT91C1, a glycosyltransferase from Oryza sativa, which is efficient at catalyzing β (1–2) glucosylation. The enzyme’s ability to bind steviol glycoside substrate in three modes underlies its flexibility to catalyze β (1–2) glucosylation in two distinct orientations as well as β (1–6) glucosylation. Guided by the structural insights, we engineer this enzyme to enhance the desirable β (1–2) glucosylation, eliminate β (1–6) glucosylation, and obtain a promising catalyst for the industrial production of naturally rare but palatable steviol glycosides.

Steviol glycosides from the plant Stevia rebaudiana are already used as lowcalorie sweeteners, but the most abundant naturally occurring compounds have a bitter aftertaste. Here, the authors characterize and engineer rice glycosyltransferase OsUGT91C1 to facilitate the large-scale production of naturally rare but palatable glycosides Reb D and Reb M

Details

Title
Catalytic flexibility of rice glycosyltransferase OsUGT91C1 for the production of palatable steviol glycosides
Author
Zhang, Jinzhu 1 ; Tang Minghai 1 ; Chen, Yujie 1 ; Ke, Dan 1 ; Zhou, Jie 1 ; Xu, Xinyu 1 ; Yang, Wenxian 1 ; He Jianxiong 1 ; Dong Haohao 1   VIAFID ORCID Logo  ; Wei Yuquan 1 ; Naismith, James H 2   VIAFID ORCID Logo  ; Lin, Yi 3 ; Zhu, Xiaofeng 1   VIAFID ORCID Logo  ; Cheng, Wei 1   VIAFID ORCID Logo 

 West China Hospital of Sichuan University, Sichuan University, Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, State Key Laboratory of Biotherapy and Cancer Center, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581) 
 West China Hospital of Sichuan University, Sichuan University, Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, State Key Laboratory of Biotherapy and Cancer Center, Chengdu, China (GRID:grid.13291.38) (ISNI:0000 0001 0807 1581); Wellcome Trust Centre of Human Genomics, Roosevelt Drive, Division of Structural Biology, Oxford, UK (GRID:grid.13291.38); Rosalind Franklin Institute, Didcot, UK (GRID:grid.507854.b) 
 Shanghai Jiao Tong University, International Peace Maternity and Child Health Hospital, Institute of Embryo-Fetal Original Adult Disease, School of Medicine, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2605423865
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.